Cite
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial.
MLA
Cardin, Dana B., et al. “Dual Src and EGFR Inhibition in Combination with Gemcitabine in Advanced Pancreatic Cancer: Phase I Results : A Phase I Clinical Trial.” Investigational New Drugs, vol. 36, no. 3, June 2018, pp. 442–50. EBSCOhost, https://doi.org/10.1007/s10637-017-0519-z.
APA
Cardin, D. B., Goff, L. W., Chan, E., Whisenant, J. G., Dan Ayers, G., Takebe, N., Arlinghaus, L. R., Yankeelov, T. E., Berlin, J., & Merchant, N. (2018). Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Investigational New Drugs, 36(3), 442–450. https://doi.org/10.1007/s10637-017-0519-z
Chicago
Cardin, Dana B, Laura W Goff, Emily Chan, Jennifer G Whisenant, G Dan Ayers, Naoko Takebe, Lori R Arlinghaus, Thomas E Yankeelov, Jordan Berlin, and Nipun Merchant. 2018. “Dual Src and EGFR Inhibition in Combination with Gemcitabine in Advanced Pancreatic Cancer: Phase I Results : A Phase I Clinical Trial.” Investigational New Drugs 36 (3): 442–50. doi:10.1007/s10637-017-0519-z.